Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Johnson and Johnson
AstraZeneca
Dow
Colorcon

Last Updated: July 3, 2022

CLINICAL TRIALS PROFILE FOR ZYLOPRIM


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Zyloprim

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00175019 ↗ Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 Completed Takeda Phase 3 2003-07-01 The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.
NCT00241839 ↗ Uric Acid and Hypertension in African Americans Completed University of Florida Phase 3 2005-08-01 This study will test the hypothesis that the administration of a xanthine oxidase inhibitor (allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood pressure (BP) control in African Americans.
NCT00430248 ↗ Efficacy and Safety of Oral Febuxostat in Participants With Gout Completed Takeda Phase 3 2007-02-01 The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
NCT00602693 ↗ T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed Masonic Cancer Center, University of Minnesota Phase 1 2007-07-23 RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T-regulatory cells after the transplant may decrease this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. However, the donor immune system may also react against the recipient's tissues (graft-versus-host disease). PURPOSE: This phase I trial is studying the side effects and best dose of donor T-regulatory cells after an umbilical cord blood transplant in treating patients with advanced hematologic cancer or other disorder.
NCT00643123 ↗ Allopurinol Add-on Treatment for Refractory Mania Completed National Alliance for Research on Schizophrenia and Depression Phase 4 2007-09-01 The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for treatment resistant mania and mixed mania.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zyloprim

Condition Name

Condition Name for Zyloprim
Intervention Trials
Gout 3
Chronic Lymphocytic Leukemia 3
Hyperuricemia 3
Leukemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zyloprim
Intervention Trials
Leukemia, Lymphoid 7
Leukemia 7
Precursor Cell Lymphoblastic Leukemia-Lymphoma 4
Myelodysplastic Syndromes 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zyloprim

Trials by Country

Trials by Country for Zyloprim
Location Trials
United States 123
Mexico 10
Canada 7
United Kingdom 1
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zyloprim
Location Trials
Texas 8
Minnesota 7
California 5
Florida 4
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zyloprim

Clinical Trial Phase

Clinical Trial Phase for Zyloprim
Clinical Trial Phase Trials
Phase 4 3
Phase 3 5
Phase 2 10
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zyloprim
Clinical Trial Phase Trials
Completed 13
Terminated 6
Recruiting 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zyloprim

Sponsor Name

Sponsor Name for Zyloprim
Sponsor Trials
Masonic Cancer Center, University of Minnesota 5
Takeda 4
M.D. Anderson Cancer Center 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zyloprim
Sponsor Trials
Other 29
Industry 10
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Merck
McKesson
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.